Drug Trial Radar · NCT01602952
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
Last checked: Nov 19, 2026Latest source record: Aug 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Jul 2008
Primary completion
Oct 2012
Study completion Jul 13, 2018
Sponsor
- Lead sponsor
- Il-Yang Pharm. Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 21, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I/II multicenter study of IY5511HCl in Philadelphia chromosome positive chronic myeloid leukemia patients without optimal response or tolerance to Bcr-Abl tyrosine kinase inhibitors (Imatinib and/ or Dasatinib, Nilotinib) In this study, The efficacy and safety of CML patients who are resistant or intolerable to imatinib in the Chronic and Accelerated phases. Phase 1 1\. To investigate the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicity (DLT) of oral Radotinib HCl bid (twice daily) in the Philadelphia chromosome-positive CML subjects who are resistant, suboptimal responsive, or intolerant to imatinib OR resistant or intolerant to at least one second-generation targeted anticancer agent while being resistant, suboptimal responsive, or intolerant to imatinib simultaneously. Phase 2 1. To investigate safety of oral Radotinib HCl in CML patients who are resistant or intolerable to imatinib in the chronic and accelerated phases. 2. To evaluate hematologic and cytogenetic efficacy of oral Radotinib HCl in CML patients who are resistant or intolerable to imatinib in the chronic and accelerated phases.
Conditions
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Philadelphia Chromosome
- Hematologic Diseases
Interventions
RadotinibDrug
50mg, 100mg or 200mg Capsule BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- To investigate the Maximum Tolerated Dose(Phase 1)Time frame: 12 month
- Rate of Complete hematologic response(CHR)(Phase 2)Time frame: 12 months
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
Local institution
Mumbai, Maharashtra, India
Local institution
Mumbai, Mazagaon, India
Local institution
Daegu, Buk-gu, South Korea
Local institution
Jeonju, Deokjin-gu, South Korea
Local institution
Ulsan, Dong-gu, South Korea
Local institution
Anyang-si, Dongan-gu, South Korea
Local institution
Hwasun, Hwasun-eup, South Korea
Local institution
Seoul, Jongro-ku, South Korea
Local institution
Busan, Seo-gu, South Korea
Seoul St. Mary's hospital
Seoul, Seocho-gu, South Korea
Local institution
Suwon, Yeongtong-gu, South Korea
Local institution
Bangkok, Phyathai, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.